Program
Nitroglycerin
Also written as “Glyceryl Trinitrate”, “MED2005” and “IMX-150”.
Its studies are mostly in Raynaud Disease · Erectile Dysfunction · Coronary Artery Disease · Fissure in Ano · Connective Tissue Diseases, led by 5 companies.
Drug pageNitroglycerin: every studyMany companies study it; this page follows only the 12 they lead. All 119 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediQuest Therapeuticsits history only | 40 open or running | phase 3since Dec 18, 2007 | May 29, 2007 | none ahead |
| Futura Medical Developmentsits history only | 30 open or running | phase 3since Jan 15, 2019 | Jun 29, 2015 | none ahead |
| AbbVieits history only | 20 open or running | phase 4since Aug 7, 2013 | Aug 28, 2007 | none ahead |
| Procris Pharmaceuticalsits history only | 20 open or running | phase 2since Mar 17, 2008 | Mar 17, 2008 | none ahead |
| Covis Pharma S.à.r.l.its history only | 10 open or running | phase 2since Feb 18, 2016 | Feb 18, 2016 | none ahead |
Also a collaborator on its studies: Merck and Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2007First study: phase 2 study in Raynaud DiseaseNew to MediQuest TherapeuticsMediQuest Therapeutics · NCT00480753 · 15 enrolled · United States
- Aug 7, 2007Phase 1 study in HealthyMediQuest Therapeutics · NCT00513994 · 6 enrolled · United States
- Aug 28, 2007AbbVie’s first study: phase 3 study in Fissure in AnoNew to AbbVieAbbVie · NCT00522041 · 248 enrolled
- Dec 18, 2007Phase 3 study in Raynaud DiseaseMediQuest Therapeutics · NCT00577304 · 200 enrolled · United States
- Mar 17, 2008Procris Pharmaceuticals’ first study: phase 2 study in Diabetic Peripheral NeuropathyNew to Procris PharmaceuticalsProcris Pharmaceuticals · NCT00641953 · 155 enrolled · United States
- Jun 13, 2008Phase 1 study in Raynaud DiseaseProcris Pharmaceuticals · NCT00700518 · 10 enrolled · United States
- Feb 9, 2009Phase 1 study in Raynaud DiseaseMediQuest Therapeutics · NCT00841594 · 12 enrolled · United States
- Aug 7, 2013Phase 4 study in Fissure in AnoAbbVie · NCT01920074 · United States
- Jun 29, 2015Futura Medical Developments’ first study: phase 2 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT02495467 · 232 enrolled · United Kingdom
- Feb 18, 2016Covis Pharma S.à.r.l.’s first study: phase 2 study in Raynaud's Phenomenon Secondary to Connective Tissue DiseaseNew to Covis Pharma S.à.r.l.Covis Pharma S.à.r.l. · NCT02688270 · 65 enrolled · United States
- Jan 24, 2018Phase 1 study in Erectile DysfunctionFutura Medical Developments · NCT04008732 · 40 enrolled · United Kingdom
- Jan 15, 2019Phase 3 study in Erectile DysfunctionFutura Medical Developments · NCT03813992 · 1,005 enrolled · Bulgaria, Czechia, Georgia and more
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ataciguatrule | Sanofi | phase 3 | 3 |
| praliciguatrule | Ironwood Pharmaceuticals | phase 2 | 8 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03813992Erectile Dysfunction · Bulgaria, Czechia, Georgia and more | 3 | Completed | Futura Medical Developments | Jul 21, 2019 | 1,005 |
| NCT04008732Erectile Dysfunction · United Kingdom | 1 | Completed | Futura Medical Developments | Apr 16, 2018 | 40 |
| NCT02688270Raynaud's Phenomenon Secondary to Connective Tissue Disease · United States | 2 | Completed | Covis Pharma S.à.r.l. | Dec 2016 | 65 |
| NCT02495467Erectile Dysfunction · United Kingdom | 2 | Completed | Futura Medical Developments | Jul 30, 2016 | 232 |
| NCT01920074Fissure in Ano · United States | 4 | Withdrawn | AbbVie | Mar 2015 | 0 |
| NCT00841594Raynaud Disease · United States | 1 | Completed | MediQuest Therapeutics | Feb 2009 | 12 |
| NCT00700518Raynaud Disease · United States | 1 | Completed | Procris Pharmaceuticals | Nov 2008 | 10 |
| NCT00641953Diabetic Peripheral Neuropathy · United States | 2 | Completed | Procris Pharmaceuticals | Mar 2008 | 155 |
| NCT00577304Raynaud Disease · United States | 3 | UNKNOWN | MediQuest Therapeutics | Mar 2008 | 200 |
| NCT00522041Fissure in Ano | 3 | Completed | AbbVie | Jul 2008 | 248 |
| NCT00513994Healthy · United States | 1 | Completed | MediQuest Therapeutics | 6 | |
| NCT00480753Raynaud Disease · United States | 2 | Completed | MediQuest Therapeutics | 15 |
How it is read
Names in the registry
- “Nitroglycerin”, 4 entries
- “Glyceryl Trinitrate”, 4 entries
- “MED2005”, 2 entries
- “IMX-150”, 2 entries
- “Nitroglycerin spray”, 1 entry
Conditions, from the studies’ own filings
- Raynaud Disease, 4 studies
- Erectile Dysfunction, 3 studies
- Coronary Artery Disease, 2 studies
- Fissure in Ano, 2 studies
- Connective Tissue Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.